Replies to post #253242 on Biotech Values

[novicetrader]

Mufaso,thanks for pointing out the details on BIOA in your prior posts. Very much appreciated, your indepth analysis on the obesity stocks has always been very helpful.

[DewDiligence]

VERU—(-48%)—reports purportedly-positive Enobosarm phase-2b data_for muscle-mass preservation by Wegovy users:

https://www.globenewswire.com/news-release/2025/01/27/3015441/11676/en/Veru-Announces-Positive-Topline-Data-from-Phase-2b-QUALITY-Clinical-Study-Enobosarm-Preserved-Lean-Mass-in-Patients-Receiving-WEGOVY-Semaglutide-for-Weight-Reduction.html

The safety database is still blinded, according to the PR.